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Abstract The worldwide emergence of antibiotic resis-
tances and the drying up of the antibiotic pipeline have
spurred a search for alternative or complementary antibac-
terial therapies. Bacteriophages are bacterial viruses that
have been used for almost a century to combat bacterial
infections, particularly in Poland and the former Soviet
Union. The antibiotic crisis has triggered a renewed clinical
and agricultural interest in bacteriophages. This, combined
with new scientific insights, has pushed bacteriophages to
the forefront of the search for new approaches to fighting
bacterial infections. But before bacteriophage therapy can
be introduced into clinical practice in the European Union,
several challenges must be overcome. One of these is the
conceptualization and classification of bacteriophage ther-
apy itself and the extent to which it constitutes a human
medicinal product regulated under the European Human
Code for Medicines (Directive 2001/83/EC). Can thera-
peutic products containing natural bacteriophages be
categorized under the current European regulatory frame-
work, or should this framework be adapted? Various actors
in the field have discussed the need for an adapted (or
entirely new) regulatory framework for the reintroduction
of bacteriophage therapy in Europe. This led to the identi-
fication of several characteristics specific to natural
bacteriophages that should be taken into consideration by
regulators when evaluating bacteriophage therapy. One
important consideration is whether bacteriophage therapy
development occurs on an industrial scale or a hospital-
based, patient-specific scale. More suitable regulatory
standards may create opportunities to improve insights into
this promising therapeutic approach. In light of this, we
argue for the creation of a new, dedicated European regu-
latory framework for bacteriophage therapy.
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Introduction
Antimicrobial resistance is a key twenty-first century global
health challenge (Cooper and Shlaes 2011; Kutateladze and
Adamia 2010). The potential of bacteriophages for treating
(multi-drug resistant) bacterial infections has been acknowl-
edged for decennia (Bru¨ssow 2005; Gill and Hyman 2010;
Go´rski et al. 2009a, b; Maura and Debarbieux 2011; Pirnay
et al. 2012) and bacteriophage research is being performed
intensively worldwide (Ackermann 2012). Bacteriophage
therapy was developed mainly in Eastern Europe (Poland)
and the former Soviet Republics (Georgia and Russia). A
handful of clinical trials have been performed in those
countries, as well as in the United States and India (Bruttin
and Bru¨ssow 2005; Monk et al. 2010); however, most of
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these studies were not carried out according to modern, evi-
dence-based standards of medical research (Parracho et al.
2012). Today, a small number of clinical trials have been
carried out and/or are ongoing and bacteriophage therapy is
being applied in clinical settings under the purview of specific
national regulatory frameworks and/or the Helsinki Declara-
tion (Go´rski et al. 2009a, b; Kutter et al. 2010).
The lack of a smooth (re-) introduction of bacteriophage
therapy in Europe is related to several obstacles within the
current European Regulatory Framework (Bru¨ssow 2012;
Pirnay et al. 2011; Verbeken et al. 2012; Wright et al. 2009).
Meanwhile, the UK’s Medicines and Healthcare Products
Regulatory Agency has approved a bacteriophage clinical trial
(Pirnay et al. 2011), which is now ongoing. In this context,
bacteriophages used as therapeutics are considered ‘‘biological
medicinal products’’ by European regulators. In the United
States, such bacteriophage-based products are handled by the
FDA division for vaccines and related product applications
(Parracho et al. 2012). This suggests that a non-specific, tech-
nical and stringent legislative pharmaceutical framework is
likely to be introduced into the field of natural bacteriophage
therapy in the near future. Hospitals using bacteriophage-based
products to treat hospitalized patients—many of which hospi-
tals have used these products for many years—must now meet
the stringent requirements pertaining to ‘‘true’’ human medic-
inal product development. This is likely to be destructive for the
non-profit (tailored) hospital-based use of therapeutic bacte-
riophages as well as for small and medium enterprises lacking
the necessary financial resources to fund the full product
development cycle for bacteriophage-based products (Pirnay
et al. 2012; Thiel 2004).
Currently, the regulatory aspect of bacteriophage ther-
apy is understudied. No technical, scientific arguments
currently exist addressing the question of whether and to
what extent bacteriophages fit within the actual definitions
and procedures of the existing regulatory framework for
human medicinal products in Europe.
This study investigates the scientific arguments related
to the classification of bacteriophages as human medicinal
products under the current European regulatory framework.
The core of the discussions was the European legislation
relevant to the therapeutic (anti-bacterial) use of natural
(not genetically modified) bacteriophages in humans.
The aim of the study was to evaluate whether the current
European regulatory framework for human medicinal products
needs to be adapted with regard to an eventual (re-) introduction
of bacteriophage therapy into the European Union.
Methodology
The research focuses on the application of natural bacte-
riophages in a therapeutic context. Other possible fields of
applications for bacteriophages (e.g., prevention of infec-
tions; use as vaccines; use as diagnostic tools; use as a tool
to influence cancer or to decontaminate skin grafts) were
excluded.
To investigate the extent to which the concept of bac-
teriophage therapy does or does not fit into the current
European regulatory framework for human medicinal
products, the existing biomedical-economic literature was
reviewed and in-depth interviews with 35 key informants
with knowledge and/or regulatory expertise of bacterio-
phages were carried out. Participants were selected using
purposive sampling. The experts represent different
stakeholder groups, including industry (11), academia (18),
hospitals (5) and competent authorities (1). The intervie-
wees were based in Belgium (15), France (8), United States
(3), United Kingdom (2), Georgia (2), Germany (1), Poland
(1), Portugal (1), Switzerland (1) and The Netherlands (1).
The interview was based on a standardized question-
naire. Three definitions from the existing European
regulatory framework were presented to the interviewees
(Boxes 1–3): the general definition of a medicinal product,
the definition of a biological medicinal product, and the
definition of an Advanced Therapy Medicinal Product
(ATMP). The interviewees were asked to comment on how
bacteriophages did or did not fit into the wordings of the
presented definitions (see Fig. 1). Beside these three main
definitions, the following topics where also discussed: the
definition of a bacteriophage, whether (or not) a bacterio-
phage is in fact a living entity, therapeutic quality and
safety issues, application methodologies, possible side
effects of bacteriophages, differences/similarities of bac-
teriophage therapy versus antibiotic therapy, marketing
authorization pathways, the hospital exemption issue and
intellectual property aspects. The interviewees were asked
to formulate conclusions about whether (or not) the current
European regulatory framework is sufficient, needs to be
adapted or whether there is a need for a new, dedicated
framework specifically for bacteriophages.
The interviews were qualitatively analyzed and consis-
tent themes and patterns were identified. Due to the
complexity of the interview data, results were processed
and analyzed using non-computational qualitative meth-
odology (Silverman 2010).
Results
This chapter summarizes the answers/the reflections of the
interviewees in relation to the questions asked. These
answers, reflections or statements do not necessary reflect
the position of the authors of this paper. Literature-refer-
ences are not included in this chapter since it is not known
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to the authors from what (publication) background the in-
terviewees were answering the questions.
Bacteriophages as Human Medicinal Products
under the European Regulatory Framework
Arguments Related to Bacteriophages and the Definition
of a Human Medicinal Product (see Box 1)
The definition of a human medicinal product (Art. 1 of
Directive 2001/83/EC) refers to a ‘‘substance’’ (or a
combination of substances) presented with particular
therapeutic properties and used in therapeutic contexts.
Such a substance is also defined in the Directive (Box 1)
and is perceived to be ‘‘any matter irrespective of ori-
gin’’, with some additional examples. The definition of
this referred substance is so broadly defined that it
includes natural bacteriophages used as antimicrobial
agents within human beings. The definition could even be
taken to cover a physician, since a physician is also
‘‘presented to patients as having properties for treating
disease’’.
In view of the particular examples of substances (Box
1), opinions differ on what a natural bacteriophage really
is. A bacteriophage can be considered a microorganism—
or not—and as living—or not. Differences at this concep-
tual level are important when considering a potential
classification of natural bacteriophages in the existing legal
framework for human medicinal products.
In the case that a bacteriophage is considered a
microorganism, we can refer to it as a bacterial virus, a
microbe or some other organism. According to classical
taxonomical terminology, a bacteriophage is indeed a
virus. A virus outside a bacterium is called a ‘‘virion’’ (an
‘‘intermediate phase’’). ‘‘Virions’’ can be compared to
spores or sperm cells. A spore is not a plant, and a sperm
cell is not a human being. Once the virion is inside the
bacterium, this bacterium is no longer the same cell. The
virion takes over the essential elements and processes
within the bacterium. The changed (infected) cell could
thus be called a ‘‘viral cell’’. It is the virus-cell combi-
nation that then produces the bacteriophages (virions). In
this view, the bacteriophage together with its bacterium
can be considered to be one microorganism, since a
bacteriophage has no existence without that bacterium.
The bacteriophage-bacterium combination could be
classified as a new taxonomic entity.
On the other hand, there are arguments supporting the
idea that a bacteriophage is not a microorganism since a
bacteriophage has no ‘‘organs’’ and requires a cell
machinery to be ‘‘alive’’. According to this logic, a bac-
teriophage can be considered as derived from a
microorganism.
With respect to its replicating nature, a bacteriophage is
perceived as a biological entity that, by interacting with its
(biological) environment, is capable of replicating and
evolving as an independent, self-replicative particle. But
others do not consider a bacteriophage self-replicative
Fig. 1 Overview of methodological approach of the interviews
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since a bacteriophage needs a host (a biological system) to
self-replicate.
Is a Bacteriophage Living? Some do not consider a
bacteriophage as a living entity since it lacks the most basic
component of a biological system, namely, a cell (the
biologic basic entity). A cell is an open thermo-dynamic
system with a constant material and energy flow. Being
alive implies a status with a ‘‘anti-entropic effect’’. This
contrasts with a bacteriophage as a (classically defined)
virus consisting only of (static) proteins and nucleic acids.
Others consider bacteriophages as living entities. Due to it
being a very small entity—a capsuled single-stranded
DNA—(the entire DNA of) a bacteriophage was one of the
first molecules to be synthesized in the laboratory.
Although very simple in design, this piece of DNA is not
functional when introduced as such into a bacterium.
Therefore, arguments can be found to qualify bacterio-
phages as ‘‘living’’. Viruses are, after all, part of the ‘‘tree
of life’’.
Therapeutic Action of Bacteriophages Bacteriophages
can ‘‘treat or prevent’’ a disease in human beings and they
‘‘restore, correct or modify physiological functions by
exerting pharmacological, immunological or metabolic
actions’’ as described in the Directive (Box 1). Different
aspects can be considered with respect to the exact mode of
action of a therapeutic bacteriophage. Bacteriophages can
restore physiological function and the original endemic
flora by controlling the pathogens present there. In this
way, they can restore balance to out-of-control systems. In
cases where different bacteria are involved, bacteriophages
can generate a competitive exclusion by specifically
attacking a particular bacterium, thus rebalancing the
ecosystem.
Another mode of action of bacteriophages relates to
their capacity to effectively modify human physiological
functions, be it in an indirect way, by destroying the bac-
teria. In this sense, they are comparable with antibiotics.
Immunological actions can be attributed to bacteriophages
by specifically boosting the human immune system. Even a
metabolic action of bacteriophages can be observed, since
bacteriophages interact with the microbial parts of the
human body, correcting or modifying physiological func-
tions by killing off pathogenic microorganisms. In
addition, bacteriophages take over the bacterial metabo-
lism. Bacteriophages can also generate a pharmacological
action since bacteriophages are not only antimicrobials but
can also suppress inflammation caused by infection.
Finally, bacteriophages can be used as a medical diag-
nostic tool (Box 1), as was the case when they were used in
salmonella testing during salmonella outbreaks and fast
plaque testing for tuberculosis.
Route of Administration of a Bacteriophage-Based Prod-
uct There is a lack of scientific evidence about the most
optimal application format and methodology for bacterio-
phage therapy. The external (topical) or oral use of
bacteriophages should pose no problems. The preferable
application method, however, is intra-peritoneal or intra-
muscular. Bacteriophages are then released into the
bloodstream very slowly, gradually and at low levels. In
this way, the immune system is stimulated much less than
it would be were the bacteriophages to be directly injected
intravenously. Once the bacteriophages are at the point of
action, they will auto-amplify as needed. Bacteriophages
have widely been used intravenously. For instance, the
intravenous anti-staphylococcal bacteriophages produced
at the Eliava Bacteriophage Institute’s industrial depart-
ment have been used across the whole Soviet Union from
the end of 1970s through the end of 1980s for treatment of
septic infections in humans (children and adults) caused by
multiple drug-resistant Staphylococcus aureus. However,
there is some sense in not administering bacteriophages
intravenously, particularly because bacteriophages are
likely to be filtered out by the immune system almost
immediately using this method. In an effort to prevent this,
one could try to cover the bacteriophages with molecules,
making them invisible to the immune system. However,
after this manipulation, the bacteriophages can no longer
be considered ‘‘natural’’ bacteriophages. Ultimately, while
promising as an avenue for further research, bacteriophages
may not be suited to treating kidney or liver infections
since maintaining adequate bacteriophage concentrations
to treat at these locations is probably infeasible.
Possible Side Effects of Bacteriophage Therapy Predicted
side effects are very few and mostly depend on the time of
administering the bacteriophages, the applied amount of
bacteriophages, the type of bacteriophages used, the format
of application, and whether the bacteriophages are
administered as cocktails.
With respect to genetic (carcinogenic) consequences
related to bacteriophage therapy, gene transfer cannot be
totally excluded, but will probably only happen at a very
low frequency.
Bacteriophages can cross the blood–brain barrier, but no
known specific side effects related to this have been
reported.
Immunological response at the moment of treatment and
immunization against the bacteriophages when used in the
long run could also be possible. This phenomenon is not
likely to appear when the treatment period is (very) short.
This is why repetitive treatment at intervals of several
weeks or months (with the same bacteriophages) should be
avoided. When using bacteriophage cocktails in a partic-
ular therapy, bacteriophages must be changed or updated
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frequently and broad-spectrum cocktails must be composed
of the least possible number of bacteriophages.
The use of therapeutic bacteriophages will lead to a quick
and in some cases quit massive destruction of the bacterial
cells involved. At worst, this massive and total lysis of
bacteria and the subsequent release of toxins could generate
potentially life-threatening reactions such as endotoxin
shock, mechanical osmotic effects or respiratory symptoms.
The use of small quantities of bacteriophages at once is
necessary in order to avoid the large-scale release of toxins.
In addition, a first, limited amount of bacteriophages prior to
a higher therapeutically relevant dose can prevent large-
scale toxin release because the initial bacteriophages destroy
the bacteria before they multiply massively.
A side effect of bacteriophage cocktails in particular is
the risk of recombination that can occur within a bacte-
riophage, ending all control over the process. Recombining
the genetic information within bacteriophages can modify
the original bacteriophages. This happens in nature and is
being studied in labs; however, more modeling studies are
necessary to fully explore this.
It is clear that the long-term consequences of bacterio-
phage therapy remain partly unknown, especially in view
of the resistance development. Although bacteriophages
can adapt and evolve along bacterial changes, research
related to the development of resistance in general and
research on bacteriophages more specifically is therefore
necessary. We must treat carefully and draw on lessons
learned in the past from the development cycle of antibi-
otics, which progressed without any profound, thorough
risk assessment. For bacteriophages, the (environmental)
risk assessment for (non-human) medical use is also
important due to problems that may arise from the massive
use of bacteriophages in, e.g., the veterinary, bio-agricul-
tural industry, as was and continues to be the case for
antibiotics use in that industry.
Views Related to Bacteriophages and the Definition
of a Biological Medicinal Product (see Box 2)
The definition of a Biological Medicinal Product refers to
the active substance as a biological substance produced or
extracted from a particular biological source. Active pro-
ducts used in natural bacteriophage therapy can be
classified under the definition of a Biological Medicinal
Product.
This is the case for several reasons. First, a natural
bacteriophage itself can be perceived as a biological sub-
stance. Such bacteriophages can be produced by or
extracted from a biological source, as proclaimed in the
Directive. The bacterium itself can be seen as the biolog-
ical source. Other possible biological sources are the initial
ecological combination ‘bacteriophage-bacterial host’, or
the bacteriophage itself, which enters a bacterial cell,
interacts with it and replicates. Even the wound fluid of the
patient or the wastewater out of which bacteriophages can
be extracted could be viewed as possible biological
sources.
It is also possible to view a bacteriophage as not
extracted from but made by the bacterial cell. The bacte-
riophage lyses the bacterial cell and releases itself from its
host. A bacteriophage has a self-replicating nature, but it
can only reproduce (or make) itself when present in a
bacterium, namely, a very bacterial-specific host or the
biological system to which it belongs.
One could also consider the endozymes produced by the
bacteriophage as active biological substances. Such endo-
zymes cause lysis of the bacterium and originate from the
bacteriophages as a biological source.
When bacteriophages are considered as human medici-
nal products, the starting material (as indicated in
Directive 2001/83/EC) for producing the therapeutic bac-
teriophage product must be a substance of biological origin
(Box 2). The exact meaning of that starting material can
differ. One can consider a microorganism as the starting
material for producing a therapeutic bacteriophage, or a
particular substance, produced by a microorganism.
Another view identifies two types of starting materials for
producing therapeutic bacteriophages, namely, ‘‘virions’’
and bacteria, forming bacterio-viruses. Yet another
approach is simply to characterize a bacteriophage’s parent
as its substance of origin.
Physico-Chemical-Biological Testing of Bacterio-
phages With respect to the characterization and
determination of the quality of a bacteriophage-based
product (Box 2), it could be argued that a combination of
physico-chemical-biological testing is required, together
with testing of the production process and its control, as
described in the Directive (Box 2). However, the exact
meaning of physico-chemical-biological testing in view of
bacteriophage therapy needs to be clarified, particularly in
relation to the required documentation package for bacte-
riophage therapy.
To generate a qualitative effect of therapeutic bacterio-
phages, the first requirement is to assess the underlying
therapeutic problem of the patient, namely to identify the
problematic bacterial strain so that the right corresponding
(most effective) therapeutic bacteriophage can be selected.
Once selected, the bacteriophage-bacterium interaction
(the efficacy) needs to be evaluated in vitro. Electron
microscopy can be helpful in documenting the interaction
bacteriophage-bacterium.
Bacteriophages need to be characterized in view of the
specific morphotype. Maximal molecular characterization
of the bacteriophage genome is mandatory to confirm the
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absence of known toxic genes or to confirm the absence of
known antibiotic-resistant genes, but not for each batch
produced (only for the master stock). In view of the genetic
testing of bacteriophages, it could be useful to have a
microchip formulation that could be used to test any
cocktail to ensure that it is not carrying a pathogenicity
island. Full genetic sequencing can, however, lead to false
safety statements since, even when a bacteriophage is fully
sequenced, half of its genome (and/or related functions)
remains unknown. The presence of lysogenic bacterio-
phages must be maximally excluded. In any case, it is also
important to point out that a bacteriophage that lacks any
lysogenic component can acquire one from a lysogenic
bacteriophage that is already present in the body. Bacte-
riophages arising from host bacteria with the lowest level
of emerging mutations must be chosen for the production
of bacteriophage preparations. When possible, bacterio-
phages should be produced in a non-pathogenic bacterial
host, and that host must be sequenced as well. This issue is
less (or not) relevant when bacteriophages are grown on the
patient’s own bacteria. In order to avoid genetic alterations,
it would be wise not to scale up the production of bacte-
riophages indefinitely. Although bacteriophages are natural
products, producing them in high quantities is not natural.
Unexpected changes could be introduced. In the case of
industrial bacteriophage preparations, permanent monitor-
ing of the production process is seen as mandatory and
must be reproducible.
Final bacteriophage preparations must be pure (absent
of residual contaminating bacteriophages, absent of (other)
hosts), sterile, endotoxin purified and pH neutral. (Endo)
toxin testing and/or pyrogenicity testing of the final pro-
ducts is/are considered necessary. The final bacteriophage
titre must be tested, as well as the (storage) stability (and
conditions).
Assessing pharmaco-kinetics of the bacteriophage
preparations (in relation to the application format, under
relevant conditions) is also beneficial. Also the (adverse)
immune response of the human body should be studied. In
vitro modeling is important to understanding the action of
the bacteriophages.
When bacteriophages are stored in a ‘‘therapeutic phage
bank’’, it would be interesting to compare the quality
management applied in such master bacteriophage banks
with that applied in human cell banks.
In contrast to this rationale, counterarguments state that
no elaborated bacteriophage quality and safety documen-
tation is necessary since the safety of bacteriophages has
been proven through their long-standing historical use.
Bacteriophages are the most abundant form of ‘‘life’’ on
earth and are even older than bacteria. If bacteriophages
were pathogenic to humans, so goes the argument, it would
be publicly known by now. According to this way of
thinking, efficacy is all that must be tested and human
clinical trials should be conducted. Historical data related
to bacteriophage therapy were not, in most cases, generated
in accordance with western research standards. Most of
these data were collected through ‘‘open’’ clinical trials in
eastern countries and lack any written decent reports or
data audits. Therefore, in order to be useful, these historical
data must be validated. In view of this, it has been sug-
gested to (partially) fall back on these historical data for
documenting bacteriophage safety. Efficacy must be pro-
ven through standardized clinical trials.
In any case, the documentation of therapeutic bacterio-
phages is something to take seriously. Data obtained
through scientifically sound clinical trials must live up to
western standards. It is important to explain (especially to
regulators) what is known about bacteriophages and their
therapeutic use and to define acceptable risks of bacterio-
phage therapy.
In the future, basic sequencing research should be per-
formed to see whether lytic bacteriophages could ever turn
into a lysogenic state. In addition, the question of how
bacteriophages can adapt to existing natural beneficial
bacteria—and what the consequences of such an adaptation
could be—should also be addressed. It remains uncertain
whether and how bacteriophages can infect eukaryotic
cells. Basic studies in vitro have to be validated in vivo.
The performance of bacteriophages in vivo can vary from
their in vitro activity. In addition, blood–brain barrier
crossings must be studied in humans as well as in mice.
Evolutionary models have also proven to be important to
the study of specific interactions between bacteria and
bacteriophages.
Natural Bacteriophages Comparable to Vaccines or Tox-
ins? From a regulatory point of view, bacteriophages are
most similar to a particular type of biological medicinal
products, namely vaccines. More in particular, bacterio-
phage cocktails used in humans need to be updated over
time, especially when bacterial resistance develops (as is
the case with the flu vaccine). For that reason, some bac-
teriophage companies are now liaising with the vaccine
unit of the European Medicines Agency (EMA).
However, bacteriophages are not ‘‘regular’’ vaccines that
are mostly used preventive to produce active immunity and
therapeutic only in particular cases. Bacteriophages on the
contrary are antimicrobials, with a secondary competence
of boosting the immune system, be it in a non-specific
manner. Since bacteriophages (or their lysates) can boost
the immune system (in different ways), they can effectively
be seen as ‘‘therapeutic vaccines’’. Using bacteriophages in
this way implies the concept of ‘‘auto-vaccination’’ via
bacteriophages, meaning vaccinating patients with their
own bacteriophages. Parallels exist in this sense between
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bacteriophage therapy and tumor vaccination. In the latter,
the patients’ own tumor tissue is taken for preparation of the
vaccine and the patient’s own immune response towards its
own tumor is modified. This immune response should be
self-limiting since the reaction has to stop when the tumor is
gone.
Triggering the immune system is not necessarily posi-
tive for the bacteriophage itself since it can be eliminated
by the immune system of the patient before destroying the
bacteria. On the other hand, bacteriophages can be used to
test the state of immunity of the patient in general.
With respect to the category of toxins, bacteriophages
are not toxic and hence they are not to be considered toxins
as described in the Directive 2001/83/EC.
Views on Bacteriophages and the Definition
of an ATMP (Box 3)
ATMPs are defined in Directive 2001/83/EC as complex
therapeutic products. Natural bacteriophages can be con-
sidered as complex products. Once administered to the
patient, control over the stability of the bacteriophage
products is lost. When bacteriophages are applied in the
wound-bed of the patient, bacteriophages can replicate in
bacteria and bacteriophage-variations and mutations can
develop. Pharmacokinetics of administered bacteriophages
(absorption process) is very complex. Sequencing and
determining the exact function (e.g., proteomics) is also
complex, as is determining the way bacteriophages realize
their therapeutic effect.
However, the actual categories within the ATMP
framework (products for gene therapy, somatic cell ther-
apy or tissue engineering) are not suitable to natural
therapeutic bacteriophages. For instance, natural bacterio-
phages are not gene therapy medicinal products since they
are not genetically modified. For obvious reasons, bacte-
riophages are not considered somatic cells therapy
medicinal products nor tissue engineered medicinal
products.
For most complex therapeutic products, a precise legal
definition is required. Since natural bacteriophages are
already present in nature and in our body, it is questionable
whether such a definition is necessary for bacteriophages.
The complexity is of a technically different nature than
gene or somatic cell therapy. Bacteriophages could be
compared to more widely used strategies for improving
microbial ecology such as probiotics.
Differences and/or Similarities of Bacteriophage Ther-
apy Versus Antibiotic Therapy.
At the product level, antibiotics are (mostly) syntheti-
cally prepared chemical products, although antibiotic
compounds isolated from nature exist as well. Natural
bacteriophages are (by definition) natural ‘‘products’’.
In terms of function, both antibiotics and bacterio-
phages modify (indirectly) human physiological functions
by destroying pathogenic bacteria. Some antibiotics act at
the genetic level while others block specific metabolic
pathways. Therapeutically relevant bacteriophages, which
are lytic natural bacteriophages, kill bacteria by other
mechanisms. Such bacteriophages destroy the bacterium
‘‘from the outside’’ by massively perforating the cell
membrane, or ‘‘from within’’ by multiplying within the
bacterium and eventually being released from that bacte-
rium. Some modern antibiotics cause lyses of the bacteria
as well. Endotoxins are released within the patient
through lyses or bacterial cell death in general. In the case
of antibiotics, this release almost never causes a major
problem for a patient confronted with major (resistant)
infections, which is what can be expected for bacterio-
phage therapy as well.
An important difference between bacteriophages and
antibiotics is that bacteriophages have a much more spe-
cific, targeted action. The broadest-spectrum bacteriophage
will never execute as wide an action as the most targeted
antibiotic product does. Therefore, bacteriophages do not
disturb the natural flora as much as antibiotics do. How-
ever, bacteriophages’ high specificity can also be
considered a negative factor for clinical application.
Another important difference is that bacteriophages are
able to diffuse in small numbers to the site of bacterial
infection and then multiply only when needed. Antibiotics,
on the other hand, must be administered in high doses right
at the site of treatment, which may cause collateral damage
to the patient.
In contrast to antibiotics, bacteriophages can cross the
blood–brain barrier (in small quantities) and perform their
action (massively) once the target bacteria are reached.
Another advantage of bacteriophages over antibiotics is the
reduced risk for development of resistance. The amount of
bacteriophages does not decrease when approaching the
bacterial target. Distinct from antibiotics, bacteriophages
have an additional capacity to act on biofilms since their
lysins can destroy the biofilm.
In view of those differences and similarities, most
experts agree that bacteriophages and antibiotics should be
used complementarily/synergistically.
Views with Respect to (Marketing) Authorization
for Bacteriophage Therapy
Two Regulatory Pathways According to the interviewees,
two (complementary) regulatory pathways should be
defined for bacteriophage therapy.
The first is a regulatory path for a uniform product
market placement of natural bacteriophage-based products.
Since bacteriophages are regarded as human medicinal
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products, the actual legal framework for human medicinal
products in Europe is applicable, implying submitting a full
product dossier (complying with Directive 2001/83/EG)
and conducting large-scale expensive clinical trials. This
path imposes several hurdles: (1) The high financial
threshold cannot easily be overcome by public stakeholders
such as hospitals without financial support from other
(government) sources. (2) The current Directive 2001/83/
EG provides insufficient technical guidance and legal cer-
tainty for the development of products for natural
bacteriophage therapy. (3) The primary aim of public
stakeholders is in fact not a real ‘‘market placement’’ or
‘‘marketing authorization’’ of a bacteriophage-based (or
any other) product. (4) One major risk of such market
placement of bacteriophage based products is the devel-
opment of large-scale resistance, at least when use is
widespread and uncontrolled. One suggestion could be to
update a standard bacteriophage cocktail preparation on a
yearly basis once it is on the market and resistance begins
to develop, as is done with the flu vaccine.
The second regulatory path should imply an approach
applicable to tailored, patient-specific treatments.
The question arises as to whether hospitals applying a
tailored bacteriophage therapy approach in close collabo-
ration with microbiological labs should be excluded from
the conventional marketing authorization requirement as
described in Directive 2001/83/EG and national laws.
Certain non-profit-driven hospitals often possess clinical
expertise to provide bacteriophage therapy but lack the
financial capacity and interest to engage themselves in
large-scale market placements of authorized bacteriophage
products. In addition, the bacteriophage itself is not a
‘‘product to be brought to the market’’ (citing the wordings
of Directive 2001/83/EC) and the tailored hospital-based
bacteriophage therapy approach is the only approach that in
reality fully exploits the clinical potential of a therapeutic
bacteriophage. Bacteriophage therapy is in fact a thera-
peutic concept.
If patient-specific use of bacteriophage therapy in hos-
pitals is made exempt from the regulatory framework
designed to receive marketing authorization (similar to the
hospital exemption rule within the regulatory framework of
advanced cell and tissues, ATMPs), quality and patient
safety must be guaranteed. It is also argued that not only
hospitals but also industry, with specific approval from
regulators, should in theory be able to deliver ‘‘out-of-
frame’’ and ‘‘tailored’’ bacteriophage preparations to
patients and hospitals on a per-request basis. However, the
difficulty and expense of applying the ‘‘one product for one
patient’’ model is not cost-efficient.
In view of this, it may be more prudent to regulate
bacteriophage therapy via a simplified marketing authori-
zation framework, feasible for hospitals as well, by strictly
defining the (often rare) indications for bacteriophages
uses. For industries interesting in market approval for
bacteriophage cocktails, endeavors to work under the
orphan drug legal frameworks should be explored.
Over-the-Counter Distribution In view of distribution,
there are arguments for a very ‘‘liberal’’ distribution
model for natural bacteriophages intended for therapeutic
use. Some argue that ‘‘over-the-counter’’ distribution of
bacteriophages will increase resistance development,
while others argue that ‘‘over-the-counter’’ distribution
should be possible on the grounds that solely hospital-
based use cannot preclude the development of resistance.
Next, others claim that limiting distribution to those who
are tested is unrealistic, since testing all patients before
allowing them to take bacteriophages would be expensive
and economically infeasible. Such pre-testing is not
readily available for other conventional drug therapies
either.
A consensus solution could be to organize over-the-
counter distribution of standard bacteriophage-based
cocktail products specifically selected for non-life-threat-
ening infections while leaving treatment in life-
threatening situations to tailored bacteriophage-based
products in a hospital environment. Most ideal would be
hospital-based (lab-linked) and accessible (cheap) use of
natural bacteriophage-based products. National ‘‘bacte-
riophage therapy centers’’ (scientific boards included) as
are now being set up in Brussels, could be of great value,
in preference when linked to a ‘‘therapeutic bacteriophage
bank’’ (e.g., DSMZ—http://www.dsmz.de) where specific
bacteriophages could be stored and produced as needed.
For any treatment, patients must be tested for the best
strain match. Individualized approaches and flexibility for
physicians to treat patients via personalized schemes
should be central.
Views on an Adapted or New Legal Framework
for Bacteriophage Therapy
Stakeholders are convinced of a need for a dedicated (new)
regulatory framework for bacteriophage therapy that
acknowledges the specific properties of bacteriophages and
their bacterial interaction as well as the role of hospitals as
providers of bacteriophage therapy. As explained above,
bacteriophages are uniquely different from conventional
human medicinal products (such as chemical substances,
somatic cell therapy products and gene therapy medicinal
products, among others) currently regulated under existing
frameworks. In view of the fact that even products for
homeopathy have a dedicated legal framework, some
question why bacteriophage therapy is not regulated in a
specified, dedicated way.
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An adapted regulatory framework could, for instance, be
inspired by the existing legislation governing ‘‘advanced
cellular and genetic therapy’’ (ATMPs), where regulators
took a binary approach towards industrial as well as hos-
pital-based use of cell and gene products and therapies.
Next to the two-way regulatory paths, a new or adapted
framework for bacteriophage therapy must in addition take
into account the different trajectories for storing and
making available therapeutic bacteriophages. (1) A first
possibility would be to use the patient’s own bacterio-
phages in a tailored approach for that individual patient. No
long-term storage of bacteriophages would be necessary,
but on-site testing facilities would have to be present
wherever this kind of tailored therapy is offered (‘‘bacte-
riophage therapy centers’’). (2) A second approach
comprises the isolation and storage of well-defined (GMP-
produced) therapeutic bacteriophages in a bacteriophage
bank, which would then be distributed as needed. Such
bacteriophages can represent starting materials for the
preparation of a cocktail that could be used for combating
broad-scale bacterial infections, e.g., in refugee camps
confronted with dysentery. At best, different bacterio-
phages targeting the same bacterium would be collected
and, if necessary, provided for therapeutic use, minimizing
resistance issues. (3) Such therapeutic bacteriophages
stored in a bank could be ordered as well by a physician for
tailored-use within a hospital.
An adapted or new regulatory framework for bacterio-
phage therapy must guarantee safety and quality.
Regulatory conditions that govern the production of human
medicinal products (e.g., Good Manufacturing Practices)
impose high costs and are perhaps not necessary to increase
the safety of bacteriophage-based products. Instead, spe-
cific guidelines solely directed at quality and safety of
bacteriophage preparations should be developed, harmo-
nized and controlled.
If regulators and legislators are to adapt existing legis-
lation (and its interpretation), public as well as private
stakeholders must agree on what type of pathways and
approaches need to be developed. All partners in these dis-
cussions will eventually come to a consensus understanding
on the use of therapeutic bacteriophages and that this
understanding will serve as a basis for moving forward in a
constructive way.
While regulatory frameworks are (and should be) the
product of negotiations with regulators and legislators, the
negotiation process takes time; time that is precious given
the acuteness of the problems faced. In view of the fact that
EMA recognized the regulatory framework of biological
medicinal products as applicable to bacteriophages, this
regulatory pathway might just be the best place to start for
further elaboration. Since the regulatory frameworks rele-
vant to the development of bacteriophage therapy are
actually more reasonable in, e.g., Australia, Canada, it is
time for Europe and individual European countries to take
action. At the same time, an international platform should
ensure that international harmonization develops.
Patenting Bacteriophage-Related Applications
Isolated, therapeutic bacteriophages can in theory be pat-
ented when a complete, well-defined documentation
package is available for the specific bacteriophage(s). This
package comprises data related to the genome sequence,
pre-clinical information, specific functionality, and specific
application, among other features. Inventive steps can be
defined on the basis of molecular characteristics, applica-
tion methodology and eventually production procedures. In
practice, patents on bacteriophage products are important
tools for attracting investors to new companies keen on
developing therapeutic bacteriophages.
Similar to most vaccine patents, a patent for a regularly
updated bacteriophage cocktail can also be sought.
Companies interested in placing therapeutic bacterio-
phages on the market take care of IP: they first choose their
most appropriate market niche, gain experience from a reg-
ulatory point of view and acquire a first return on investment.
In a next step, after building more experience on the subject,
expansion to other markets can proceed. IP protection is
important in order to be able to develop this pathway.
Discussion
Directive 2001/83/EC defines a human medicinal product,
the types of action, its sources and its starting materials.
This definition is formulated rather broadly, encompassing
natural bacteriophages. For instance, for the products cov-
ered by its scope, the Directive does not differentiate
between ‘‘direct’’ or ‘‘indirect’’ therapeutic actions. Bacte-
riophages generate their action on the patient in an indirect
way, similar to antibiotics. Bacteriophages destroy the
bacterial pathogen and consequently eradicate or decrease
the pathogenic bacterial load in the patient (Payne and
Jansen 2003).
It is clear from our analysis that natural bacteriophages
fit into the definition of a ‘‘biological medicinal product’’
(Box 2). However, different biological sources for the
production of a therapeutically active bacteriophage are
possible. Since the definition of a biological medicinal
product does not limit the types of potential biological
sources, therapeutic bacteriophages also comply with the
definition of a biological medicinal product. However,
therapeutic bacteriophages do not fit into the Special
Frames (indicated in the Directive 2001/83/EG) applicable
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to biological medicinal products, such as vaccines, toxins
and serum-derived products.
In view of the applicability of the ATMP definition (in
Regulation 1394/2007) to bacteriophages, it is not clear
whether bacteriophages are ‘‘complex therapeutic products
with technical specificities requiring precise legal definitions’’
(as is true for ATMPs). In a sense, the regulatory pathways
developed for ‘‘natural’’ ATMPs might provide a historical
reference point. Products used in somatic cell therapy, when
substantially manipulated or used in a non-homologous way,
are classified as ATMPs. The human medicinal product
Directive 2001/83/EC defines ‘‘cultivation’’, for instance, as a
substantial manipulation. Consequently, natural bacterio-
phages, when cultivated, could also be seen as fitting within
the ATMP framework since they would, according to this
definition, be substantially manipulated.
Impact of Classifying Natural Bacteriophages
as Human Medicinal Products
The development of a human medicinal product, either as a
biological medicinal product (Dir 2001/83/EG) or as an
ATMP (Dir 2001/83/EG and Regulation 1394/2007)
requires huge investments of time and money. The non-
profit sector and the diverse interested small and medium
enterprises can hardly afford this pathway without external
investments. Therefore, there is a need for products like
natural bacteriophages to be exempted from the scope of
the regulatory framework applicable to human medicinal
products, more specific Directive 2001/83/EG and Regu-
lation 1394/2007, depending on whether bacteriophages
are seen as biologics or ATMPs.
One way would be not to formulate the therapeutic
action of the bacteriophage as a primary mode of action,
arguing that such a product is not a human medicinal
product. However, this is not the most optimal scenario
when the ultimate goal of the exercise is ‘‘to bring thera-
peutic bacteriophages to the patient’’ (Mie˛dzybrodzki et al.
2012; Soothill 2013; Wittebole et al. 2013). In addition, by
reviewing the definitions, all reviewers acknowledged that
a bacteriophage may fit into the definition of a human
medicinal product.
Another way is to use exemptions within the existing
regulatory framework for human medicinal products. If
natural bacteriophages are considered ATMPs, the ATMP
Regulation 1394/2007 is applicable. This framework only
specifies certain categories, human somatic cell therapy,
gene therapy and tissue engineering. A specific category
‘‘viral therapy’’ could theoretically be introduced under this
ATMP framework. In any case, the ATMP Regulation
1394/2007 provides a possibility for hospitals to be
exempted from a stringent centralized marketing
authorization, referred to as the ‘‘hospital exemption’’ (Art.
28 of Regulation (EC) No. 1394/2007). National rules
apply to hospital exempted-ATMPs. However, if present,
such rules are in any case specifically designed for cell and
tissue based therapies, not bacteriophage therapy. In addi-
tion, often such national rules require similar GMP as
requested for fully centralized marketing authorization
dossiers. Therefore, a specific Directive covering natural
bacteriophage therapy (to be implemented in national laws
specific for bacteriophage therapy) is desirable.
If natural bacteriophages are considered biological human
medicinal products, Directive 2001/83/EG applies. Unfor-
tunately, the Directive 2001/83/EG (currently) does not
provide for a hospital exemption (as in the ATMP Regula-
tion). But Article 3 (Paragraph 1) of Title II of the Directive
states that it ‘‘shall not apply to any medicinal product pre-
pared in a pharmacy in accordance with a medical
prescription for an individual patient (commonly known as
the magisterial formula).’’ However, a (hospital) pharmacist
is not supposed to use non- (EU) licensed products as com-
ponents for magisterial preparations. Since natural
bacteriophages are not licensed products at the moment, this
potential pathway could be difficult to implement.
Another way to escape the marketing authorization
requirement is to consider the scope of that Directive.
Article 2, Par. 1 (Title II) of the Human Medicinal Product
Directive states that it ‘‘shall apply to medicinal products
for human use intended to be placed on the market in
Member States and either prepared industrially or manu-
factured by a method involving an industrial process’’. As
highlighted by the interviewees, a tailored (natural) bac-
teriophage production (Merabishvili et al. 2009),
performed within a hospital for use on particularly defined
patients can hardly be seen as an ‘‘industrial production’’.
In addition, the therapeutic, in-house use of these produced
bacteriophages is not ‘‘market placement’’. Hospitals are
not interested in producing human medicinal products for
the purpose of obtaining a ‘‘marketing authorization’’ for
further distribution. For these reasons, and analogous to the
logic developed in the field of the cellular ATMPs, the
tailored production and therapeutic use of natural bacte-
riophages on humans would appear not to be covered by
the scope of the Human Medicinal Product Directive. The
industrial productions of uniform bacteriophage products
intended for European market placement, on the other
hand, are covered by the scope of this Directive.
If natural bacteriophages would be covered by the scope
of the Directive 2001/83/EG, a new hospital exemption
needs to be designed for biological human medicinal pro-
ducts, accompanied by a specific Directive for bacteriophage
therapy (to be implemented in national laws).
It is clear from the above that there is a regulatory gap
for natural bacteriophage therapy. While regulators are
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responsible for applying a regulation, the regulation itself
can only be changed through legislative action, which is in
this case highly needed to guarantee a timely, flexible and
sustainable way of introducing bacteriophage therapy in
Europe.
The appropriate legal action we suggest is a European
wide Directive for Natural Bacteriophage Therapy. Such
Directive should regulate documentation requirements of
safety, potency, purity and toxicity, specific in the context
of hospital based patient-tailored (natural) bacteriophage
therapy. (Industrial) stakeholders aiming to bring pharma-
ceutical products based on natural bacteriophages to the
market could be exempted from the scope of the new
Directive and follow the classical medicinal product
approach instead (see Fig. 2).
The creation of a bacteriophage-specific Directive could
find inspiration on the evolution of what has transpired the
last several decennia in the field of human cell and tissue
engineered products. As early as the seventies, hospitals
were using processed human cells and tissue in treatments for
their patients, in accordance with the respective national
legislation, until the European Human Cell and Tissue
Directive was published in 2004 (Directive 2004/23/EC of
the European Parliament and the Council of 31 March 2004).
This Directive still applies to all work with human body
material today and focuses mainly on the hospital-based
development and use of cellular products. A few years later,
in 2007, the ATMP Regulation (EC) No. 1394/2007 came
into force. This ATMP regulation focused (and still does)
mainly on industrial work with human bodily material. At the
same time, it allows for a ‘‘hospital exemption’’. The hospital
exemption applies to non-industrial, tailored and hospital-
based clinical use of cell and gene based ATMPs. Industrial
ATMPs meant for market placement are regulated at the
European level while hospital-based (non-industrial) pro-
ductions are regulated at the national level.
In a similar way, the bacteriophage-specific regulatory
framework with its specific Directive should (1) distinguish
between hospital-based (tailor-made) use of natural thera-
peutic bacteriophages in patients on the one hand and
Fig. 2 Proposal for a new European directive for bacteriophage therapy
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industrial production and distribution of uniform bacterio-
phage products on the other, (2) define specific quality and
safety criteria relevant to the use of natural bacteriophages
on patients (Merabishvili et al. 2009; Wright et al. 2009),
(3) define a specific efficacy documentation package rele-
vant to (natural) bacteriophages, (4) make it possible to
give patients in need instant access to natural bacteriophage
therapy (Caplin 2009), (5) only define requirements rele-
vant to natural bacteriophages, and (6) fully exploit the co-
evolutionary aspects of natural bacteriophages (Krylov
2011; Levin and Bull 2004; Scanlan and Buckling 2012).
Close dialogue, open discussions and information exchange
with the EMA and national authorities is crucial. It is thus of
high importance that regulators and legislators (Members of
Parliament) be persuaded of the prudence of a dedicated Bac-
teriophage Therapy legal framework for Europe.
Conclusions
A dedicated European Bacteriophage Therapy Legal
Framework is a prerequisite for paving the way to the
smooth introduction of natural bacteriophage therapy into
western medicine. If Europe refuses to support the short-
term (safe) implementation of ‘‘hands-on’’ bacteriophage
therapy in its member states, the national authorities of the
member states should step into assert their responsibility in
this respect. Antibiotic resistance is an acute problem, both
in public health terms and socio-ethical terms. 25 000
Europeans die each year as a direct consequence of un-
treatable bacterial infections (Ackermann 2012). There is
an urgent need for national bacteriophage therapy centers.
Industry can play an important role in this. When bacte-
riophage therapy centers are unable to (financially) launch
themselves, national governments should provide sufficient
support and/or stimulate the creation of new pharmaco-
economic environments.
Box 1. Definition of a Human Medicinal Product
within the Directive 2001/83/EC of the European
Parliament and the Council of 6 November 2001
on the Community code relating to medicinal products
for humans use. Consolidated | 2001L0083-EN-
21.07.2011-010.002-1. Words written in Italic are
subject to interpretation, as discussed
in the manuscript.
According Art. 1(2) of the Medicinal Product Directive
2001/83/EC, a Human Medicinal Product is a substance
or a combination of substances presented as having
properties for treating or preventing disease in human
beings. According the same Directive, a Medicinal
Product can also be a substance or a combination of
substances which may be used in or administered to
human beings either with a view to restoring, correcting
or modifying physiological functions by exerting a
pharmacological, immunological or metabolic action, or
to making a medical diagnosis. The substance referred to
in the Directive is any matter irrespective of origin
which may be: human, e.g., human blood and human
blood products; animal, e.g., microorganisms, whole
animals, parts of organs, animal secretions, toxins,
extracts, blood products; vegetable, e.g., microorganisms,
plants, parts of plants, vegetable secretions, extracts;
chemical, e.g., elements, naturally occurring chemical
materials and chemical products obtained by chemical
change or synthesis.
Box 2. Definition of a Biological Medicinal Product.
Words written in Italic are subject to interpretation,
as discussed in the manuscript
According to Part I Module 3 (3.2.1.1) of the Medicinal
Product Directive 2001/83/EC, a Biological Medicinal
Product is a Medicinal Product of which the active
substance is a biological substance. A biological sub-
stance is a substance that is produced by or extracted
from a biological source and that requires for its char-
acterization and the quality determination a combination
of physico-chemical-biological testing, together with the
production process and its control. The Directive pro-
vides specific requirements for particular biological
medicinal products such as vaccines, toxins and sera, in
particular, for agents used to produce active immunity,
such as cholera vaccine, BCG, polio vaccines, smallpox
vaccine; agents used to diagnose the state of immunity,
including in particular tuberculin and tuberculin PPD,
toxins for the Schick and Dick Tests, brucellin; and
agents used to produce passive immunity, such as
diphtheria antitoxin, anti-smallpox globulin, antilympho-
cytic globulin. According the Directive (Part I Module 3
(3.2.1.1), the starting materials of a Biological Medicinal
Product shall mean any substance of biological origin
such as microorganisms, organs and tissues of either
plant or animal origin, cells or fluids (including blood or
plasma) of human or animal origin, and biotechnological
cell constructs (cell substrates, whether they are recom-
binant or not, including primary cells).
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Box 3. Definition of Advanced Therapy Medicinal
Product (ATMP) from Regulation (EC) No 1394/2007
of the European Parliament and the Council of 13
November 2007 on advanced therapy medicinal
products and amending Directive 2001/83/EC
and Regulation (EC) No 726/2004 | Official Journal
of the European Union | 10.12.2007 | L324:121-137.
Words written in Italic are subject to interpretation,
as discussed in the manuscript.
The Regulation 1394/2007 on ATMPs (Recital 3) describes
ATMPs as complex therapeutic products with technical
specificities requiring precise legal definitions. Under the
ATMP Regulation, Products for Somatic Cell Therapy,
Tissue Engineered Products as well as Gene Therapy
Medicinal Products (GTMPs) are classified as ATMPs.
According to Part IV of Annex I to Directive 2001/83/EC,
a Gene Therapy Medicinal Product is a biological medic-
inal product that has the following characteristics: (a) It
contains an active substance which contains or consists of a
recombinant nucleic acid used in or administered to human
beings with a view to regulating, repairing, replacing,
adding or deleting a genetic sequence; (b) Its therapeutic,
prophylactic or diagnostic effect relates directly to the
recombinant nucleic acid sequence it contains, or to the
product of genetic expression of this sequence. Gene
therapy medicinal products shall not include vaccines
against infectious diseases.
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